• Lannett launches generic version of Advair Diskus in the US

  Aurobindo Pharma announced that its newly-acquired US subsidiary Lannett has launched 100/50 mcg and 250/50 mcg strengths of a generic version of Advair Diskus fluticasone propionate / salmeterol xinafoate DPI in the US. Aurobindo notes that… [Read more . . .]

• ENA Respiratory awarded almost AU$3 million funding to support Phase 1b trial of INNA-051 intranasal dry powder TLR2/6 agonist in patients with asthma

  According to ENA Respiratory, the company has received AU$2.98 million in funding from the new Australian “national virtual incubator” Biointelect Venturer, with the funds going to support a Phase 1b study of ENA’s INNA-051 dry powder… [Read more . . .]

• Milestone Pharmaceuticals initiates Phase 3 ReVerA-301 trial of etripamil nasal spray (Cardamyst) for AFib-RVR

  Milestone Pharmaceuticals has announced the initiation of the Phase 3 ReVeRA-301 study of etripamil nasal spray in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial is expected to enroll about 150 patients who… [Read more . . .]

• Silo Pharma gets notice of allowance for Canadian patent covering SPC-15 intranasal therapy for PTSD

  According to Silo Pharma, the company has received a notice of allowance from the Canadian Intellectual Property Office related to a patent application titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” covering SPC-15… [Read more . . .]

• Rein Therapeutic’s LTI-03 inhaled dry powder synthetic peptide gets Fast Track designation for the treatment of IPF

  According to Rein Therapeutics, the FDA has granted the company’s LTI-03 inhaled dry powder synthetic peptide Fast Track designation for the treatment of idiopathic pulmonary fibrosis. The company notes that the FDA previously granted orphan… [Read more . . .]

• Bespak’s Holmes Chapel site gets Gold EcoVadis sustainability rating

• NeOnc reports that Phase 2a trial of NEO100 intranasal perillyl alcohol in patients with brain tumors met its primary endpoint

• Scienture launches Rezenopy naloxone nasal spray in the US

• Zydus launches Revahale revefenacin inhalation solution for the treatment of COPD in India

• ReCode Therapeutics names Heather Clark as its new CEO

More news . . .